CTI BioPharma Corp. (CTIC)

0.76
NASDAQ : Health Technology
Prev Close 0.76
Day Low/High 0.73 / 0.79
52 Wk Low/High 0.60 / 2.11
Avg Volume 132.50K
Exchange NASDAQ
Shares Outstanding 57.98M
Market Cap 43.83M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Biotech Stock Mailbag: Year in Review

Biotech Stock Mailbag: Year in Review

Biotech stock watchdog Adam Feuerstein looks back at the best and worst of Mailbag 2009.

Cell Therapeutics Gets FDA Panel for Lymphoma Drug: BioBuzz

Cell Therapeutics Gets FDA Panel for Lymphoma Drug: BioBuzz

Pixantrone will be reviewed by an FDA advisory panel on Feb. 10.

Biotech Calendar: Upcoming FDA Dates

Biotech Calendar: Upcoming FDA Dates

A quick and dirty guide to the expected regulatory news from the FDA through June 2010.

Biotech Stock Mailbag: Cell Therapeutics

Biotech Stock Mailbag: Cell Therapeutics

Biotech columnist Adam Feuerstein answers reader email about Cell Therapeutics and other stocks.

Cell Therapeutics on Dilution Watch: BioBuzz

Cell Therapeutics on Dilution Watch: BioBuzz

CEO spotted in New York with bankers in tow, looking at his wallet.

Judges: Seattle Biotech Can Pursue $23M Claim

Judges: Seattle Biotech Can Pursue $23M Claim

Federal appeals court: Seattle biotech can pursue $23 million claim against former consultant

Poniard's CEO Pulls a Belichick: BioBuzz

Poniard's CEO Pulls a Belichick: BioBuzz

Risky late-game call puts Poniard in a deep financial hole.

A Closer Look at Cardium's Wound-Healing Drug: BioBuzz

A Closer Look at Cardium's Wound-Healing Drug: BioBuzz

Is it the drug or the gel that worked best in a phase II study?

Cell Therapeutics Lavishes Free Stock on Execs: BioBuzz

Cell Therapeutics Lavishes Free Stock on Execs: BioBuzz

'Retention' bonus awarded to CEO Jim Bianco, his management team and directors.

Oculus, Bianco and Cel-Sci Oh My!: BioBuzz

Some Friday Fall tidbits from the biotech stock world.

Midday Movers: Pump Up the Volume

Midday Movers: Pump Up the Volume

Several small-cap stocks were moving on above-average volume during Thursday's session.

Cell Therapeutics' Opaxio Data Not Terrible: BioBuzz

Cell Therapeutics' Opaxio Data Not Terrible: BioBuzz

More work needs to be done before penciling in approval.

Cell Therapeutics Seeks EU Aid For Cancer Drug

Cell Therapeutics Seeks EU Aid For Cancer Drug

Cell Therapeutics says it asked EU regulators to grant orphan drug status to pixantrone

Biotech Mailbag: Myriad Pharma

Biotech Mailbag: Myriad Pharma

Adam Feuerstein fields questions on Myriad Pharma, Hemispherx, Cell Therapeutics, Gilead and more.

Cell Thera Tries Bait-and-Switch With Opaxio

Cell Thera Tries Bait-and-Switch With Opaxio

Cell Therapeutics has withdrawn its European approval application for the lung cancer drug Opaxio. But you wouldn't quite get that from the company's statement Monday.

Biotech Stock Mailbag: Cyclacel Pharma

Biotech Stock Mailbag: Cyclacel Pharma

Adam details his whereabouts on Sept. 9 and tackles readers' questions about Cyclacel, Epicept and a few more familiar names.

Takeout Rumors Lift Dendreon, Bio Stocks: BioBuzz

Takeout Rumors Lift Dendreon, Bio Stocks: BioBuzz

On a strong day for the sector, the buyout rumors are buzzing

Auxilium Shares Higher On FDA Drug Review: BioBuzz

Auxilium Shares Higher On FDA Drug Review: BioBuzz

FDA doesn't raise new safety issues for Auxilium's hand treatment

XOMA to Repay Goldman Loan: BioBuzz

XOMA to Repay Goldman Loan: BioBuzz

Drug company removes overhang on balance sheet

Cell Therapeutics CEO Sells Stock: BioBuzz

Cell Therapeutics CEO Sells Stock: BioBuzz

Jim Bianco unloads 30% of holdings days after investor meeting.

Biocryst Flu Drug Missing From CDC Guidelines: BioBuzz

Biocryst Flu Drug Missing From CDC Guidelines: BioBuzz

Investors waiting for government to buy emergency stockpile of peramivir

Spectrum shares fall despite drug approval: BioBuzz

Spectrum shares fall despite drug approval: BioBuzz

Uncertainty over Zevalin's relaunch likely weighing on stock price

Osiris Stem Cell Drug Fails: BioBuzz

Negative results announced from two phase III studies in graft-versus-host-disease

Spectrum Says FDA Grants New Zevalin Approval

Spectrum Pharma says FDA approved Zevalin as first-line treatment for non-Hodgkin's lymphoma

Spectrum's Zevalin OK'd for New Use

Spectrum's Zevalin OK'd for New Use

The FDA says Spectrum can market Zevalin as a first-line consolidation therapy for NHL patients.

Weighing Arena's Obesity Drug: Biotech Mailbag

Readers weigh in on Arena Pharmaceuticals' obesity drug, Affymax's stock, and Cell Therapeutics' pixantrone.

Cell Therapeutics' Pixantrone: Priority Review or Not?

FDA review status of Cell Therapeutics' key cancer drug Pixantrone is unclear.

Cell Therapeutics Submits Cancer Drug To FDA

Cell Therapeutics Submits Cancer Drug To FDA

Cell Therapeutics says FDA will review experimental drug for cancer

Readers' Picks: TheStreet.com's Top 10

Readers' Picks: TheStreet.com's Top 10

Outrage on Citigroup and the Fed and Adam Feuerstein's biotech calendar.

Stock Search: Citigroup, Bank of America

Stock Search: Citigroup, Bank of America

Citigroup retains the top spot in TheStreet's Stock Search list today, as it seemingly has since the dawn of time. New entries to the list include ValeS.A., AIG, Rentech and Ford.

TheStreet Quant Rating: D (Sell)